Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for Prevention of Acute Mountain Sickness
NCT02604173Phase 3Completed
- Sponsor
- Stanford University
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of EPI-EE in acute mountain sickness (AMS) (3 arms), sponsored by Stanford University. Primary endpoint: Number of Participants With Acute Mountain Sickness at 24 hours. Started Aug 2016; status: completed.
02
Drugs
EPI-EE
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on NCT02604173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604173.